BioCentury
ARTICLE | Clinical News

Abiraterone acetate: Additional Phase I/II data

March 9, 2009 7:00 AM UTC

Additional data from the open-label, U.S. Phase I/II COU-AA-002 trial in 31 evaluable patients showed that 24 (77%) patients experienced a >30% decline in PSA, 22 (71%) had a decline of >50% and 8 (26...